Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. (4th July 2017)

• Record Type: Journal Article
• Authors: Cowan, Renee A.; O'Cearbhaill, Roisin E.; Zivanovic, Oliver; Chi, Dennis S.
• Is Part Of: International journal of hyperthermia. Volume 33:Number 5(2017)
• Page Start: 548
• Page End: 553
• Publication Date: 2017-07-04
• Subjects: Ovarian cancer -- surgery -- hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) -- clinical trials; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2017.1283066
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: The natural history of advanced-stage epithelial ovarian cancer is one of clinical remission after surgery and platinum/taxane-based intravenous (IV) and/or intraperitoneal (IP) chemotherapy followed by early or late recurrence in the majority of patients. Prevention of progression and recurrence remains a major hurdle in the management of ovarian cancer. Recently, many investigators have evaluated the use of normothermic and hyperthermic intraoperative IP drug delivery as a management strategy. This is a narrative review of the current status of clinical trials of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in ovarian cancer and the future directions for this treatment strategy. The existing studies on HIPEC in patients with epithelial ovarian cancer are mostly retrospective in nature, are heterogeneous with regards to combined inclusion of primary and recurrent disease and lack unbiased data. Until data are available from evidence-based trials, it is reasonable to conclude that surgical cytoreduction and HIPEC is a rational and interesting, though still investigative, approach in the management of epithelial ovarian cancer, whose use should be employed within prospective clinical trials.